Copyright
©The Author(s) 2003.
World J Gastroenterol. Feb 15, 2003; 9(2): 225-232
Published online Feb 15, 2003. doi: 10.3748/wjg.v9.i2.225
Published online Feb 15, 2003. doi: 10.3748/wjg.v9.i2.225
Table 1 Relationships between espression of E-cadherin and β-catenin an clinicopathological parameters in patients with ESCC
Group | Total | E-cadherin | P | β-catenin | P | ||||
+ | ± | - | rs | + | ± | - | rs | ||
Histologic grade | |||||||||
I | 17 | 8 | 8 | 1 | 9 | 6 | 2 | ||
II | 69 | 25 | 33 | 11 | 0.001 | 21 | 28 | 20 | 0.014 |
III | 20 | 3 | 7 | 10 | -0.309 | 2 | 12 | 6 | -0.238 |
Tumor size (cm) | |||||||||
< 3.0 | 10 | 6 | 2 | 2 | 0 | 5 | 5 | ||
3.0-5.0 | 41 | 16 | 18 | 7 | 15 | 15 | 11 | ||
5.0-7.0 | 44 | 11 | 24 | 9 | 0.054 | 12 | 24 | 8 | 0.213 |
≤ 7.0 | 11 | 3 | 4 | 4 | -0.187 | 5 | 2 | 4 | -0.212 |
Clinical staging | |||||||||
I | 2 | 2 | 0 | 0 | 0 | 2 | 0 | ||
IIa | 31 | 16 | 11 | 4 | 13 | 13 | 5 | ||
IIb | 10 | 2 | 5 | 3 | 0.013 | 3 | 2 | 5 | 0.124 |
III | 60 | 15 | 31 | 14 | -0.241 | 6 | 27 | 17 | -0.150 |
IV | 3 | 1 | 111 | 1 | 0 | 2 | 1 | ||
Venous invasion | |||||||||
Yes | 27 | 5 | 14 | 8 | 0.042 | 6 | 12 | 9 | 0.237 |
No | 79 | 31 | 34 | 14 | -0.198 | 26 | 34 | 19 | -0.116 |
Lymph nodemetastasis | |||||||||
Yes | 47 | 11 | 22 | 14 | 0.014 | 13 | 21 | 13 | 0.646 |
No | 59 | 25 | 26 | 8 | -0.239 | 19 | 25 | 15 | -0.045 |
Table 2 Relationships between E-cadherin and β-catenin expression in ESCC
E-cadherin | Total | β-catenin | ||
+ | ± | - | ||
+ | 36 | 17 | 13 | 6 |
± | 48 | 11 | 24 | 13 |
- | 22 | 4 | 9 | 9 |
Total | 106 | 32 | 46 | 28 |
Table 3 Multivariate results in Cox proportional hazards analysis for patients with ESCC
Variables | Category (Value) | β | Wald | P Value | HR | 95%CI |
Overall survival (n = 106) | ||||||
location (mid-thoracic) | No/Yes (0/l) | 0.650 | 5.665 | 0.017 | 1.916 | 1.112-3.272 |
Lymph node metastasis | No/Yes (0/l) | 0.599 | 5.893 | 0.015 | 1.821 | 1.1222-953 |
Venous invasion | No/Yes (0/l) | 1.147 | 18.633 | < 0.00l | 3.148 | 1.870-5.229 |
Clinical staging | I/II/III/IV (0/1/2/3) | 0.420 | 8.475 | 0.004 | 1.521 | 1.147-2.018 |
E-cadherin | -/ ± /+ (0/1/2) | -0.431 | 5.687 | 0.017 | 0.650 | 0.456-0.926 |
Disease-free survival (n = 96) | ||||||
Gender | M/F (0/1) | 0.675 | 4.786 | 0.029 | 1.965 | 1.073-3.598 |
Tumor size | Continue | 0.179 | 4.302 | 0.038 | 1.196 | 1.010-1.417 |
Clinical staging | I/II/III/IV (0/1/2/3) | 0.272 | 3.233 | 0.042 | 1.313 | 0.976-1.767 |
Location (mid-thoracic) | No/Yes (0/l) | 0.615 | 4.111 | 0.043 | 1.849 | 1.021-3.349 |
Venous invasion | No/Yes (0/l) | 0.982 | 9.797 | 0.002 | 2.671 | 1.444--4.942 |
E-cadherin | -/ ± /+ (0/1/2) | -0.397 | 4.479 | 0.034 | 0.672 | 0.465-0.971 |
- Citation: Zhao XJ, Li H, Chen H, Liu YX, Zhang LH, Liu SX, Feng QL. Expression of e-cadherin and β-catenin in human esophageal squamous cell carcinoma: relationships with prognosis. World J Gastroenterol 2003; 9(2): 225-232
- URL: https://www.wjgnet.com/1007-9327/full/v9/i2/225.htm
- DOI: https://dx.doi.org/10.3748/wjg.v9.i2.225